Please use this identifier to cite or link to this item:
https://hdl.handle.net/2445/224341| Title: | Novel RRAGD Variants in Autosomal Dominant Kidney Hypomagnesemia and Therapeutic Perspectives |
| Author: | Adella, Anastasia Jouret, François Madariaga, Leire Leermakers, Pieter A. Arango, Pedro Ariceta, Gema B. Beck, Bodo Bjerre, Anna Bockenhauer, Detlef Coccia, Paula Dhamija, Radhika De Frutos, Fernando Garcia-castano, Alejandro Van Katwijk, Sara B. Lucas, Jesus Möller, Thomas Müller, Dominik Pinto E Vairo, Filippo Raki, Melinda Rips, Jonathan Peter Schlingmann, Karl Venselaar, Hanka Vernet Machado Bressan Wilke, Matheus Nijenhuis, Tom Hoenderop, Joost De Baaij, Jeroen |
| Issue Date: | 29-Jul-2025 |
| Publisher: | Elsevier BV |
| Abstract: | Introduction: Variants in the Ras-related GTPase D (RRAGD) gene have been associated with autosomal dominant kidney hypomagnesemia (ADKH) characterized by hypokalemia, nephrocalcinosis, and dilated cardiomyopathy (DCM). RRAGD, which encodes for the RagD protein, is involved in the activation of the mechanistic target of rapamycin complex 1 (mTORC1). Owing to the limited characterization of patients' phenotypes, the understanding of RRAGD-associated ADKH (ADKH-RRAGD) remains incomplete. Consequently, available treatment strategies are primarily symptomatic and insufficient. Methods: In the present case series, 13 new patients and 3 novel RRAGD variants, that is, p.(Ser77Phe), p. (Thr91Ile), and p.(Ile100Arg), are described. To assess the pathogenicity of the novel variants, an in vitro assay of mTORC1 activity was performed. In addition, the clinical response to diuretics (furosemide and thiazide, n = 4) and Na+-glucose cotransporter 2 (SGLT2) inhibitor, dapagliflozin (n = 6) was evaluated in patients carrying the RRAGD p.(Thr97Pro) variant during routine. Results: The patients presented with kidney tubulopathies, including hypomagnesemia, hypercalciuria, and nephrocalcinosis. Five patients also exhibited DCM. In vitro assays demonstrated constitutive activation of noncanonical mTORC1 signaling caused by the p.(Ser77Phe) and p.(Ile100Arg) variants. Clinically, patients remained sensitive to diuretic challenges, whereas dapagliflozin treatment increased serum magnesium (Mg2+) levels by 0.04 mM but exacerbated hypokalemia. Conclusion: To date, 37 patients with ADKH-RRAGD have been identified. Kidney tubulopathy is the most prominent feature within the phenotypic spectrum of ADKH-RRAGD. Molecularly, constitutive activation of noncanonical mTORC1 is present in most RRAGD variants. From a therapeutic perspective, dapagliflozin may increase serum Mg2+ levels in patients with RRAGD variants. (c) 2025 International Society of Nephrology. Published by Elsevier Inc. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). |
| Note: | Reproducció del document publicat a: https://doi.org/10.1016/j.ekir.2025.07.035 |
| It is part of: | Kidney International Reports, 2025, vol. 10, issue. 10, p. 3640-3655 |
| URI: | https://hdl.handle.net/2445/224341 |
| Related resource: | https://doi.org/10.1016/j.ekir.2025.07.035 |
| Appears in Collections: | Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) |
Files in This Item:
| File | Description | Size | Format | |
|---|---|---|---|---|
| 1-s2.0-S2468024925004796-main.pdf | 7.57 MB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.
